Form 4: Former Director's Share Conversion Post-Merger
Insider Transaction Report
A former director of Helix Acquisition Corp. II reported the conversion of 30,000 shares into common stock of BridgeBio Oncology Therapeutics, Inc. following a business combination and domestication.
Summary
- Albert A. Holman III, a former director of Helix Acquisition Corp. II (now BridgeBio Oncology Therapeutics, Inc. [BBOT]), filed a Form 4.
- The filing reports the conversion of 30,000 Class B ordinary shares into Class A ordinary shares, and subsequently into 30,000 shares of the Issuer's common stock.
- This transaction occurred on August 11, 2025, in connection with the business combination between Helix Acquisition Corp. II and TheRas, Inc.
- The conversion was part of Helix's domestication process, where it migrated to and domesticated as a Delaware corporation from a Cayman Islands entity.
- The Class B ordinary shares converted on a one-for-one basis into Class A ordinary shares, which then converted on a one-for-one basis into common stock of the Issuer.
Sentiment
Score: 5
Explanation: Neutral. This is a routine compliance filing detailing a structural share conversion and a director's resignation post-merger, reflecting pre-announced corporate actions rather than new operational or financial performance.
Future Outlook
The filing does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction, focusing solely on a past structural transaction and a former director's share ownership changes.
Management Comments
- Albert A. Holman III was a director of Helix prior to the Domestication and resigned from such role effective as of August 11, 2025, immediately prior to the Domestication.
Industry Context
This Form 4 filing is a standard compliance disclosure following a SPAC business combination and domestication. It reflects the finalization of a pre-announced corporate restructuring, where a special purpose acquisition company (SPAC) merges with a target company (TheRas, Inc.) and changes its corporate domicile, leading to changes in share classes and ownership structures for pre-existing shareholders and directors.
Comparison to Industry Standards
- The conversion of Class B shares to Class A, and then to common stock, is a standard procedure in SPAC business combinations and subsequent domestication processes, aligning with typical industry practices for such corporate actions.
- The reporting of beneficial ownership changes by a former director via Form 4 is a routine compliance requirement for publicly traded companies, consistent with SEC regulations for insider transactions.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| Director | Albert A. Holman III | N/A | 08/11/2025 | Resigned immediately prior to the domestication of Helix Acquisition Corp. II into BridgeBio Oncology Therapeutics, Inc. |
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Corporate Structure Change | Helix Acquisition Corp. II migrated to and domesticated as a Delaware corporation in accordance with Section 388 of the Delaware General Corporation Law and the Cayman Islands Companies Act (As Revised). | 08/11/2025 | This domestication changes the company's legal domicile and governing corporate law, typically simplifying regulatory compliance and aligning with U.S. corporate standards for a publicly traded entity. |
| Share Class Conversion | Each of Helix's Class B ordinary shares converted into one Helix Class A ordinary share, and subsequently each Class A ordinary share converted into one share of the Issuer's common stock. | 08/11/2025 | Simplifies the capital structure by consolidating different share classes into a single common stock, which is standard post-SPAC merger and domestication. |
Stakeholder Impact
- Shareholders: The conversion of Class B and Class A ordinary shares into common stock simplifies the ownership structure for existing shareholders of Helix, now shareholders of BridgeBio Oncology Therapeutics, Inc.
Key Dates
| Date | Description |
|---|---|
| 08/11/2025 | Transaction date for share conversion and effective date of resignation for Albert A. Holman III as director of Helix. |
Keywords
SEC Form 4, Beneficial Ownership, Share Conversion, Business Combination, Domestication, BridgeBio Oncology Therapeutics, BBOT, Helix Acquisition Corp. II, TheRas Inc., Corporate Governance
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.